New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
04:55 EDTFCSC, FCSC, FCSC, SNY, SNY, SNY, GSK, GSK, GSK, NVS, NVS, NVS, PFE, PFE, PFE, SAFC, SAFC, SAFC, CLDX, CLDX, CLDX, CELG, CELG, CELG, WX, WX, WX, XON, XON, XON, OPXA, OPXA, OPXA, BLUE, BLUE, BLUE, BIIB, BIIB, BIIBPhacilitate to hold a forum
Cell & Gene Therapy Forum 2014 is being held in Washington, D.C. on January 27-29.
News For FCSC;BLUE;OPXA;XON;WX;CELG;CLDX;SAFC;PFE;NVS;GSK;SNY;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 12, 2015
17:54 EDTFCSCOn The Fly: After Hours Movers
Subscribe for More Information
16:15 EDTFCSCFibrocell Science receives rare pediatric disease designation for FCX-007
Fibrocell Science announced that the FDA has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB. The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa, or DEB, which includes RDEB.
16:06 EDTOPXAOpexa Therapeutics reports Q1 EPS (12c), consensus (15c)
Subscribe for More Information
09:26 EDTNVSNovartis Animal Health issued FDA warning letter over marketing materials
Subscribe for More Information
09:23 EDTXONIntrexon CEO says Ziopharm acqusition could be 'attractive' in future
Subscribe for More Information
09:20 EDTXONOn The Fly: Pre-market Movers
Subscribe for More Information
07:35 EDTXONBofA/Merrill to hold a conference
Subscribe for More Information
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
05:55 EDTXONIntrexon price target lowered to $45 from $50 at Mizuho
Subscribe for More Information
May 11, 2015
19:15 EDTXONOn The Fly: After Hours Movers
Subscribe for More Information
17:36 EDTPFEAthersys down 10.1% after Pfizer notified that it will terminate agreement
Subscribe for More Information
17:34 EDTPFEAthersys receives notification that Pfizer will terminate agreement
Subscribe for More Information
16:40 EDTXONIntrexon declares special dividend of Ziopharm shares
Subscribe for More Information
16:36 EDTXONIntrexon reports Q1 EPS 25c, consensus (5c)
Subscribe for More Information
16:33 EDTPFEPfizer takes minority interest in AM-Pharma, secures option to acquire company
AM-Pharma and Pfizer announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of $87.5M for the minority equity interest and exclusive option, with additional potential payments of up to $512.5M upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed. “Pfizer is committed to advancing the science to address the high unmet medical need in Acute Kidney Injury,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “Clinical data for recAP show the potential to uniquely address Acute Kidney Injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients.”
15:54 EDTNVS, GSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
14:34 EDTBLUEbluebird bio June volatility elevated on sharp rally
bluebird bio May call option implied volatility is at 73, June is at 109, August is at 82; compared to its 90-day average of 86, suggesting large near term price movement.
07:51 EDTBLUEConference should be positive turning point for bluebird bio, says SunTrust
SunTrust expects data due to be released at the EHA conference to create a positive turning point for bluebird bio. The firm notes that the data will include information on a sickle cell patient treated with bluebird's LentiGlobin, and the firm thinks that LentiGlobin is an effective sickle cell treatment. The firm now includes sickle cell in its estimates for the company and raised its price target on the shares to $205 from $115. It keeps a Buy rating o nthe stock.
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use